다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cancer research : the official organ of the American Association for Cancer Research, Inc, v.68 no.10, 2008년, pp.3835 - 3843
Nam, Jeong-Seok (1Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea) , Terabe, Masaki , Mamura, Mizuko (3Vaccine Branch and) , Kang, Mi-Jin (1Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea) , Chae, Helen , Stuelten, Christina (2Laboratory of Cancer Biology and Genetics) , Kohn, Ethan , Tang, Binwu (2Laboratory of Cancer Biology and Genetics) , Sabzevari, Helen , Anver, Miriam R. (2Laboratory of Cancer Biology and Genetics) , Lawrence, Scott , Danielpour, David (2Laboratory of Cancer Biology and Genetics) , Lonning, Scott , Berzofsky, Jay A. (2Laboratory of Cancer Biology and Genetics) , Wakefield, Lalage M.
AI-Helper
AbstractOverexpression of transforming growth factor β (TGF-β) is frequently associated with metastasis and poor prognosis, and TGF-β antagonism has been shown to prevent metastasis in preclinical models with surprisingly little toxicity. Here, we have used the transplantable 4T1 mode...
10.1016/j.bbcan.2006.06.004 Pardali K, Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775: 21-62.
10.1038/ng1001-117 Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
Gold LI. The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncog 1999; 10: 303-60.
10.1158/1078-0432.CCR-07-1654 Teicher BA. Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 2007; 13: 6247-51.
10.1038/nrc1926 Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-20.
10.1016/j.cytogfr.2005.09.008 Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17: 19-27.
10.1146/annurev.immunol.24.021605.090737 Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
10.1126/science.1090922 Bhowmick NA, Chytil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51.
10.1038/nature04846 Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006; 441: 1015-9.
10.1172/JCI200215333 Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-15.
10.1172/JCI0215234 Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551-9.
10.1084/jem.20022227 Terabe M, Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-52.
10.2174/156800906778742460 Saunier EF, Akhurst RJ. TGF β inhibition for cancer therapy. Curr Cancer Drug Targets 2006; 6: 565-78.
10.1038/nrd1580 Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-22.
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-405.
10.1081/IPH-120020473 Ruzek MC, Hawes M, Pratt B, et al. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 2003; 25: 235-57.
10.1158/0008-5472.CAN-06-0068 Nam JS, Suchar AM, Kang MJ, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res 2006; 66: 6327-35.
10.4049/jimmunol.142.5.1536 Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β2 affinity purification. J Immunol 1989; 142: 1536-41.
10.1016/0022-1759(94)00322-N Danielpour D, Roberts AB. Specific and sensitive quantitation of transforming growth factor β3 by sandwich enzyme-linked immunosorbent assay. J Immunol Methods 1995; 180: 265-72.
10.1096/fasebj.11.12.9337152 Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH. Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low-dose γ-irradiation. FASEB J 1997; 11: 991-1002.
Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129-36.
10.3892/or.5.2.485 Sminia P, Barten AD, van Waarde MA, Vujaskovic Z, van Tienhoven G. Plasma transforming growth factor β levels in breast cancer patients. Oncol Rep 1998; 5: 485-8.
10.1073/pnas.0932636100 Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003; 100: 8430-5.
Bandyopadhyay A, Lopez-Casillas F, Malik SN, et al. Antitumor activity of a recombinant soluble β-glycan in human breast cancer xenograft. Cancer Res 2002; 62: 4690-5.
10.1172/JCI116871 Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993; 92: 2569-76.
10.1158/0008-5472.CAN-04-1013 Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954-61.
10.1158/1078-0432.CCR-06-0162 Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 2006; 12: 4315-30.
10.1158/1078-0432.CCR-03-0611 Suzuki E, Kapoor V, Cheung HK, et al. Soluble type II transforming growth factor-β receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10: 5907-18.
10.1158/0008-5472.CAN-06-2389 Suzuki E, Kim S, Cheung HK, et al. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67: 2351-9.
10.1158/1078-0432.CCR-07-1157 Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13: 5262-70.
10.4049/jimmunol.172.12.7335 Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40.
10.1073/pnas.90.21.9944 Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc Natl Acad Sci U S A 1993; 90: 9944-8.
10.1038/nri1199 Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-90.
10.1158/0008-5472.CAN-04-1627 Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64: 7596-603.
10.1016/j.cytogfr.2004.11.002 Sanchez-Capelo A. Dual role for TGF-β1 in apoptosis. Cytokine Growth Factor Rev 2005; 16: 15-34.
Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999; 59: 1273-7.
10.1007/BF02700021 Witham TF, Villa L, Yang T, et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003; 64: 63-9.
10.4049/jimmunol.178.5.2883 Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol 2007; 178: 2883-92.
10.1038/nm1001-1118 Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001; 7: 1118-22.
10.1158/0008-5472.CAN-04-3169 Zhang Q, Yang X, Pins M, et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005; 65: 1761-9.
10.4049/jimmunol.169.7.3485 Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C. Reconstitution of lethally irradiated adult mice with dominant negative TGF-β type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 2002; 169: 3485-91.
10.1158/1535-7163.MCT-06-0109 Zhang Q, Yang XJ, Kundu SD, et al. Blockade of transforming growth factor-β signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther 2006; 5: 1733-43.
10.1016/S1074-7613(00)80170-3 Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-81.
10.1073/pnas.90.2.770 Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90: 770-4.
10.1158/0008-5472.CAN-08-0206 Nam JS, Terabe M, Kang M-J, et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008; 68: 3915-23.
10.1007/s11373-007-9201-3 Li J, Dong X, Xu Z, et al. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. J Biomed Sci 2008; 15: 99-105.
10.1073/pnas.0611660104 Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci U S A 2007; 104: 3460-5.
10.1126/science.1139158 Putnam NH, Srivastava M, Hellsten U, et al. Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization. Science 2007; 317: 86-94.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.